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Abstract Clostridium botulinum C3 exoenzyme specifically 
ADP-ribosylates rho-p21 in eukaryotic ells. Trp Is and Glu 173 of 
this enzyme were substituted with other amino acids via site- 
directed mutagenesis. All substitutions at Glu 173 caused a signifi- 
cant reduction in affinity for NAD and diminished ADP- 
ribosyltransferase activity. On the other hand, the activity of 
enzymes with the substitution at Trp Is remained intact. Swiss 3T3 
cells treated with the enzyme with the Trp TM substitution showed 
the typical morphologic hanges of the C3 exoenzyme phenotype. 
In contrast, no changes were found in cells incubated with the 
Glu~73-substituted nzyme. These results indicate that the Glu 173 
residue of the C3 exoenzyme plays a key role in interacting with 
NAD and in expression of ADP-ribosyltransferase activity, 
which is essential for the phenotypic hange by C3 exoenzyme 
treatment. 
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suggested to be involved in the NAD binding of C3 exoenzyme. 
In one study, we labeled the protein with a photoaffinity probe, 
[32p]nicotinamide-2-azidoadenine dinucleotide, and isolated a 
peptide corresponding to Phe9-Gly 19 as the adenine ring binding 
domain. Based on this, we suggested that Trp 18 may be the 
critical residue [13]. Another study affinity-labeled a C3-1ike 
exoenzyme from Clostridium limosum with [carbonyl-J4C]NAD 
by UV irradiation and suggested that the Glu ~73 residue of the 
C3 exoenzyme was a part of the NAD binding site of the 
catalytic center [14]. 
In this study, we have utilized site-directed mutagenesis to 
substitute various amino acids in place of the Trp 18 and Glu 173 
residues and then examined the importance of these residues in 
NAD binding and enzymatic activity. The substitution of 
Glu Iv3 dramatically reduced both the affinity for NAD and its 
ADP-ribosyltransferase activity, whereas no change was ob- 
served with the Trp is substitution. 
2. Materials and methods 
I. Introduction 
Bacterial mono-ADP ribosyltransferases catalyze the trans- 
fer of an ADP-ribose moiety of NAD to specific target proteins 
in eukaryotic ells, thereby affecting their functions. Examples 
of this family of enzymes include diphtheria toxin and pertussis 
toxin, which specifically ADP-ribosylate and inactivate longa- 
tion factor 2 and a heterotrimeric G protein Gi, respectively 
[1,2]. Clostridium botulinum C3 exoenzyme [3] specifically ADP- 
ribosylates the small molecular weight GTP binding protein rho 
p21 at the Asn 41 residue located in a putative effector binding 
domain [4]. Treatment of cells with C3 exoenzyme inhibits 
stimulus-induced actin filament organization and cell adhesion 
[5-12], indicating that rho p21 mediates these cellular responses 
as a molecular switch and that C3 exoenzyme inhibits these 
functions of rho p21. Identification of the amino acid residues 
of the C3 exoenzyme interacting with NAD is important in 
elucidating the structure of its catalytic site and in understand- 
ing a mechanism of the ADP-ribosylation. Two sites have been 
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2.1. Construction fmutant C3 exoenzyme expression vectors 
A cDNA clone for the C3 exoenzyme truncated at Leu tTz (173C3) was 
generated by polymerase chain reaction (PCR) using the forward 
primer 5'-ATAGGATCCCATAT-GGCTAGCTATGCAG-3' and the 
reverse primer 5'-CAACATCTAGAGTTGTCCCGGGAAATA-Y, 
with pET3a C3 [3] as the template. The PCR fragment was digested 
with NdeI and XbaI, and then cloned into pET3a vector, resulting in 
a pET3a 173C3 plasmid. The Glu ~73 substitution with Gin (E 173Q) was 
prepared by PCR using the forward primer 5'-ATTTCCCGGGA- 
CAACTGCAGGTGTTGC-3' and the reverse primer 5'-GCCTCTA- 
GAGGATCCTATTATTTAAATATCATTGC-3'. This PCR product 
was digested with SmaI and then cloned into pET3a 173C3 to give rise 
to pET3a E173Q. pET3a E173D (Asp substitution) was prepared as 
described for pET3a E173Q, except hat 5'-ATTTCCCGGGACAA- 
CTTGACGTCTTGC-Y was used as a forward primer. 
The Trp 1~ substitution with Gly (W18G) was generated as follows. 
First, PCR was performed using the forward primer 5'-GTTGAG- 
GAAGGCCAAAAAAGGTGGAAATGCTCAATATAAAAAATAT- 
G-3' and the reverse primer 5'-TTATTGGATCCTATTATTTAAAT 
ATCATTGCTGTAA-3'. The purified PCR product was served as a 
template for the second series of PCR using the forward primer 5'- 
ACTGTTCATATGGCTAGCTATGCAGATACTTTCACAGAATTT 
AC CA ATGTTGAGGAAGCCAAAAAA-Y and the identical reverse 
primer as was used in the first PCR. This was followed by digestion with 
NdeI and BamHI, and then the PCR fragment was cloned into a pET3a 
vector, resulting in pET3a W18G. pET3a W18A (Ala substitution) was 
constructed as described for pET3a W18G, except that 5"-GTTGAG- 
GAAGCCAAAAAAGCTGGAAATGCTCAATATAAAAAATATG 
-3' was used as a forward primer in the first set of PCR. All plasmids 
were sequenced to verify the correct substitutions. 
2.2. Expression a d purification of mutant C3 exoenzyme 
E. coli strain BL21 (DE3) cells carrying the plasmid vectors were 
grown at 37°C with shaking in M9 medium containing 1mM MgSO4, 
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0.1 mM CaC12, 0.5% (w/v) Casamino acids, 0.4% (w/v) glucose and 0.1 
mg/ml ampicillin. When the absorbance at 600 nm of the cell suspension 
reached 0.5, isopropyl-l-thio-fl-D-galactopyranoside wa  added to a 
final concentration of 1mM. Three hours later, the cells were harvested 
by centrifugation at 5000 × g for 10 rain. Whole cell lysates were pre- 
pared as reported previously [3], were diluted and applied to a CM 
Sepharose column equilibrated with 20 mM Hepes-NaOH (pH 7.5). 
After washing the column with the equilibration buffer, elution was
performed with a linear salt gradient between 0 and 0.5 M NaCI in the 
equilibration buffer. 
2.3. ADP-ribosylation a d cell culture 
The ADP-ribosyltransferase activity of the wild type and mutant C3 
exoenzymes was measured as follows. The ADP-ribosylation buffer 
contained 100 mM Tris-HC1 (pH 8.0), 10 mM thymidine, 10 mM 
nicotinamide, 10mM dithiothreitol, 5 mM MgCI 2, and [32P]NAD (1000 
dpm/pmol) (Dupont New England Nuclear). Purified wild type or mu- 
tant C3 exoenzyme was incubated with 1 ,ug of recombinant GST-rho 
A p21 (fusion protein) or with 100/tg protein of crude cell homogenate 
in this buffer and quantification of the ADP-ribosylation was carried 
out as previously described [12]. 
Phenotypic changes induced by the wild type an mutant C3 exoen- 
zymes and in situ ADP-ribosylation f rho p21 in cultured cells were 
examined as follows. Swiss 3T3 cells were cultured in DMEM contain- 
ing 10% fetal bovine serum until near confluent. The cells were then 
treated with or without 30pg/ml of the various C3 exoenzymes for72 h. 
During treatment, the morphology of the cells was examined under a 
phase-contrast microscope and photographed. The cells were then 
rinsed twice with phosphate-buffered saline (PBS) and incubated with 
0.05% (w/v) trypsin in PBS. The dissociated cells were collected, resus- 
pended in the ADP-ribosylation buffer as above and sonicated. The 
ADP-ribosylation reaction wasthen carried out as described above. 
3. Results and discussion 
Previous studies using two different photoaffinity probes 
[13,14] suggested two residues of the C3 exoenzyme, Trp TM and 
Glu 173, as parts of the NAD binding site. We used a site-directed 
mutagenesis technique and tested the relative importance ofthe 
two residues. We replaced Trp 1~ with Gly (W18G) or Ala 
(W18A), replaced Gill ~73 with Asp (E173D) or Gln (E173Q), 
and examined the effects of these substitutions on the ADP- 
ribosyltransferase ctivity of C3 exoenzyme. These mutant and 
wild type C3 exoenzymes were expressed in E. coli and purified 
using CM-Sepharose column chromatography. Each prepara- 
tion showed a single protein band on SDS-polyacrylamide g l
electrophoresis (Fig. IA). As shown in Fig. 1B, the ADP-ri- 
bosylation of GST-rho p21 by the wild type or the WI8A or 
W18G mutants of the C3 enzyme proceeded linearly with time 
with almost he same reaction rates. ADP-ribosylation by the 
E173D mutant proceeded also linearly, but the rate was about 
one-tenth of that of the wild type enzyme. In contrast, no 
ADP-ribosylation was detected in the reaction using the E 173Q 
mutant. To quantitatively compare the enzymatic activities of 
each mutant, the ADP-ribosylation reaction was performed 
with various concentrations of the enzymes in the presence of 
20 pM NAD. As shown in Fig. 1C, the enzymes with the 
substitution atTrp TM showed essentially the same dose-activity 
relationship as the wild type, indicating that these substitutions 
did not affect the activity. In contrast, a conservative substitu- 
tion of Glu 173 to Asp caused a decrease in the catalytic a tivity 
(>10 fold) under the same assay conditions. Furthermore, 
ADP-ribosylation was not detected with up to 1000 ng of the 
E173Q mutant C3 exoenzyme, indicating that this mutant 
showed a substantial reduction (> 10000 fold) in catalytic activ- 
ity. These results indicate that Glu 173 forms a critical site within 
the active center of the enzyme. 
We next determined whether the mutant exoenzymes showed 
a change in their binding affinity for NAD. To test this, the 
ADP-ribosylation reaction was performed using various con- 
centrations of NAD, and the affinities ofthe enzymes for NAD 
were determined. As shown in Fig. 1 D, the enzymes substituted 
at Trp 18 demonstrated lower Km values than the wild type n- 
zyme, indicating that the Trp 18 substitution did not adversely 
alter the NAD binding. In contrast, he Glu 173 substitution with 
Asp reduced the affinity for NAD about 88 fold, and little 
ADP-ribosylation activity was observed with the E173Q mu- 
tant with up to 50/.tM NAD. The Km values for NAD calcu- 
lated from double-reciprocal plots of the wild type and the 
W18G, W18A and E173D mutants of the C3 exoenzymes were 
0.125 pM, 0.098 /.zM, 0.096 /IM and 11.1 pM, respectively. 
These results demonstrate hat Glu 173 plays a key role in the 
binding with NAD. 
C3 exoenzyme has been widely used in many systems to 
examine the involvement of rho p21 and its functions. Although 
the enzyme specifically ADP-ribosylates rho p21 and the ob- 
served effect is then presumably due to an inhibition of the rho 
p21-mediated function, these experiments sometimes lack a 
proper control. Therefore, to test if the reported phenotypic 
changes induced by the C3 exoenzyme treatment were due to 
the ADP-ribosyltransferase ctivity of the enzyme, we exam- 
ined the effects of the C3 exoenzyme mutants on cultured cells. 
Swiss 3T3 cells were treated with 30 pg/ml of the wild type or 
mutant C3 exoenzymes for 72 h. Fig. 2A shows the [32p]ADP- 
ribosylation reaction of lysates from control and C3 exoen- 
zyme-treated cells. [32P]ADP-ribosylation f rho p21 in cells 
incubated with the wild type, W18G, W18A, E 173D and E 173Q 
mutants were 19, 22, 25, 105 and 107% of the control cells, 
respectively. This indicates that the exoenzymes with the substi- 
tution at Trp 18 did not display any significant change in their 
ADP-ribosylation activity in situ in these cells, whereas the 
exoenzymes with the replacement a Glu 173 showed no enzy- 
matic activity in situ, which was consistent with the results 
obtained by the in vitro experiments. Fig. 2B-E show the mor- 
phology of the Swiss 3T3 cells treated with the wild type and 
mutant C3 exoenzymes. As reported previously [12], cells 
treated with the wild type enzyme demonstrated a marked cell 
rounding, with beaded endritic processes (Fig. 2C). The cells 
treated with the Trp~8-substituted C3 exoenzymes showed the
same morphology as cells treated with the wild type C3 (Fig. 
2D). In contrast, he cells incubated with the E173D or E173Q 
mutants did not show any of the phenotypic changes observed 
in cells treated with the wild type enzyme (Fig. 2E). Taken 
together, the results suggest that t e ADP-ribosylation activity 
of the mutant enzymes are strongly correlated with the pheno- 
typic changes in the 3T3 cells, indicating that the inhibition of 
rho p2I-mediated signalling by ADP-ribosylation i duces the 
specific morphological changes hown in Fig. 2C. 
The present study has thus shown that the Glu 173 residue 
plays a critical role in NAD binding and in both the catalytic 
and biological activities of the C3 exoenzyme. Previous tudies 
by other groups have compared amino acid sequence of C3 
exoenzyme with t ose of other mono ADP-ribosyltransferases 
and aligned this residue with Glu ~48 in diphtheria toxin, Glu 553 
in Pseudomonas exotoxin A, Glu 112 in E. coli heat-labile entero- 
toxin and Glu 24° in rabbit muscle ADP-ribosyltransferase 
[14,15]. Mutagenesis studies have revealed that all of these Glu 
residues are essential in the NAD binding and the ADP- 
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Fig. 1. (A) Purification of the wild type and mutant C3 exoenzymes. The wild type (lane 1) and the W18G (lane 2), W18A (lane 3), E173D (lane 
4) and E173Q (lane 5) mutants of the C3 exoenzyme were expressed in E. coli and purified. Three ¢tg of protein from each enzyme were subjected 
to SDS-PAGE on a 12% polyacrylamide g l, and then stained with Coomassie Brilliant blue. The positions of molecular weight markers are indicated 
on the left. (B) Time course of ADP-ribosylation with the wild type and mutant C3 exoenzymes. GSTorho p21 was incubated with 20/IM [32p]NAD 
and with 3 ng of the wild type (e) or the W18G (m), W18A (o), E173D (D) or E173Q (A) mutant in a total volume of 50 ,ul at 30°C for indicated 
times. 32p incorporation was quantified by cutting out the GST-rho p21 bands and determining their radioactivity. The relative ADP-ribosylation 
was expressed as a ratio of the 32p incorporated into GST-rho p21 at each point out of the maximal 32p incorporation given by the wild type C3 
exoenzyme in the reaction. (C) Dose-response curves for the ADP-ribosyltransferase activity of the C3 exoenzyme and its mutants. GST-rho p21 
was incubated with 20/IM [32p] NAD and the indicated amounts of the wild type (e) or the W18G (I), W18A (O), E173D ([]) or E173Q (A) mutants 
of the C3 exoenzyme at 30°C. After 5 rain, the reaction was terminated and the ADP-ribosylation of rho p21 was analyzed. (D) Kinetic analysis of 
the wild type and mutant C3 exoenzymes. GST-rho p21 was incubated with the indicated concentrations of [32p]NAD and 3 ng of the wild type (o) 
or the W18G (I), W18A (©), E173D ([]) or E173Q (A) mutants of the C3 exoenzyme at 30°C for 5 min. 
ribosyltransferase activity of the respective nzymes [15-19]. 
Recent X-ray crystallographic analyses of exotoxin A, heat- 
labile enterotoxin and diphtheria toxin have revealed a striking 
similarity in the structure of the enzymatic domains of these 
toxins, which form a prominent cleft presumably for NAD,  and 
that the Glu residues noted above are located within this cleft 
[20- 22]. In addition, several aromatic amino acid residues were 
located at or near this cleft, such as Tyr 439, Yrp 466 and Tyr 47° 
in exotoxin A, Tyr 6 in heat-labile nterotoxin, Tyr 65 and Trp 5° 
in diphtheria toxin. With their planar rings, these aromatic 
residues are presumed to provide a stacking interaction with the 
nicotinamide and adenine rings of NAD [19,23]. Indeed, the 
Tyr 65 residue in diphtheria toxin was suggested as a binding site 
for the adenine ring of NAD by a photolabeling experiment 
using 8-azidoadenine [24]. By an experiment using a similar 
photoaffinity probe, 2-azidoNAD, we previously isolated a 
peptide corresponding to Phe9-Gly 19 near the N terminus as the 
adenine ring binding domain and suggested that Trp 18 may be 
the critical residue [13]. However, on the contrary to our expec- 
tation, mutations of this residue did not alter the NAD binding 
nor the enzymatic activity of the C3 exoenzyme. These results 
suggested that if the above part of the protein does interact with 
the adenine ring, Trp TM does not play an essential role in NAD 
binding and catalysis. 
C3 exoenzyme has been used to elucidate the role of rho p21 
in various cellular functions [5-12,24-29]. There have been, 
however, no reports using site-directed nzyme mutants to 
demonstrate the relationship between its ADP-ribosylation ac- 
tivity and the biological response. In this study, using the mor- 
phological change in Swiss 3T3 cells as an index of the response, 
we showed that mutant enzymes defective in enzyme activity 
could not induce the typical phenotype. These inactive enzymes 
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Fig. 2. Effects of the wild type and mutant C3 exoenzymes on Swiss 3T3 cells. A, autoradiogram of the [32p]ADP-ribosylation of cell lysates. 3T3 
cells were treated with buffer alone (lane 1), or with the wild type (lane 2), W18G (lane 3), W18A (lane 4), E173D (lane 5) or EI73Q (lane 6) mutants 
of the C3 exoenzyme for 72 h. After treatment, cell lysates were prepared and incubated with 100 ng of the wild type C3 exoenzyme and 20/tM 
[32p]NAD at 30°C for 2 h. The positions of the molecular weight markers are indicated on the left. The position of the ADP-ribosylated rhoop21 
is indicated by an arrow. (B-E) morphology of control cells (B), cells treated with the wild type (C), the W18G (D) and the E173Q (E) mutants of 
the C3 exoenzyme for 72 h. Cells treated with the W18A or the E173D mutants showed the same phenotypic hange as with the W18G or E173Q 
mutants, respectively. Bar, 15/~m. 
will be useful as controls in experiments using the C3 exoen- 
zyme for investigating the function of rho p21-mediated signal 
transduction in many biological systems. 
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